A PHASE I, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF SATRALIZUMAB IN ADULT PATIENTS WITH APQ4 ANTIBODY-POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH BODYWEIGHT >100 KG
- Registry ID
- WP44131
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2023-05-09
- Completion date
- 2023-11-14
- Last update
- 2022-12-07
Conditions
- NEUROMYELITIS OPTICA SPECTRUM DISORDER
Related clinical trials
- A PHASE 2/3, OPEN-LABEL, HISTORICAL-CONTROLLED, SINGLE-ARM, MULTICENTER SMDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF RAVULIZUMAB IN CHILDREN AND ADOLESCENTS WITH AQUAPORIN-4 ANTIBODY POSITIVE (AQP4-AB [+]) NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
- SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
- A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
- A PHASE 2/3 OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND ACTIVITY OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA SPECTRUM DISORDER
- A PHASE 3, EXTERNAL PLACEBO-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY, OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
View on source registry